10-K: Encision Inc. Reports Fiscal Year 2024 Results, Focuses on AEM Technology Growth

Encision Inc. reported a decrease in revenue for fiscal year 2024, while highlighting its commitment to expanding its patented Active Electrode Monitoring (AEM) technology.

Summary

• Encision Inc., a medical device company, released its annual report for the fiscal year ended March 31, 2024.
• The company experienced a 7% decrease in net product revenue, totaling $6,431,969, compared to $6,885,158 in the previous fiscal year, primarily due to a decrease in non-essential surgical procedures.
• Net service revenue also decreased significantly to $153,913 from $463,356 in the prior year, which included revenue from a Master Services Agreement with Auris Health, Inc.
• Gross profit decreased by 22% to $3,135,962, with a gross profit margin of 48%, down from 55% in the previous year, due to higher product vendor costs and increased inventory reserves.
• Operating expenses decreased by 13% to $3,776,745, with sales and marketing expenses down 20% due to decreased commissions.
• Research and development expenses also decreased by 24% to $621,894.
• The company reported a net loss of $691,783 for the fiscal year, an increase from the $323,945 loss in the previous year.
• Encision had cash and equivalents of $42,509 at the end of the fiscal year and working capital of $1,206,252.
• The company has an accumulated deficit of $22,617,329 as of March 31, 2024.
• Encision believes its cash resources and borrowing capacity will be sufficient to fund operations for at least the next twelve months.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While the company has a promising technology and is making efforts to expand its market reach, the financial results for the year are concerning, with decreased revenue, gross profit, and increased losses. The company also has material weaknesses in internal controls and is dependent on external funding. The forward-looking statements are cautiously optimistic, but the risks are significant.

Positives

• Encision's AEM technology is endorsed by various groups, including surgeons, nurses, and the medicolegal community.
• The company has a broad range of AEM instruments available, making it easier for hospitals to convert to their technology.
• Encision is expanding its distribution network and pursuing relationships with GPOs and hospital systems.
• The company is developing new devices that integrate AEM technology.
• Encision has a strong intellectual property position with 16 unexpired US patents.
• The company believes its cash resources and borrowing capacity will be sufficient to fund operations for at least the next twelve months.

Negatives

• Encision experienced a decrease in both product and service revenue in fiscal year 2024.
• The company's gross profit and gross profit margin decreased significantly.
• Encision's net loss increased compared to the previous fiscal year.
• The company has an accumulated deficit of $22,617,329.
• Encision's internal controls over financial reporting were deemed not effective due to inadequate segregation of duties.
• The company's cash and cash equivalents decreased to $42,509 at the end of the fiscal year.

Risks

• The company's products may not be accepted by the market.
• Encision may need additional funding to support its operations.
• The company faces intense competition from larger, well-financed companies.
• Encision's products are subject to extensive government regulations.
• The company depends on single-source suppliers for certain key components.
• Product liability claims may exceed the company's current insurance coverage.
• The company is dependent on key personnel.
• Cybersecurity-related attacks could negatively affect the business.
• The company's common stock is thinly traded and subject to price volatility.

Future Outlook

Encision expects to generate increased sales in the U.S. from new and existing hospital customers, and to grow AEM instrumentation sales. The company plans to focus on the clinical, economic, and safety benefits of AEM technology, a medico-legal initiative, and new AEM products. They also aim to achieve cost reductions through internal manufacturing and increase research and development to expand their product line. The company believes its cash resources and borrowing capacity will be sufficient to fund operations for at least the next twelve months.

Management Comments

• Management believes that the unique performance of AEM technology and the breadth of independent endorsements provide an opportunity for market share growth.
• Management believes that the market awareness of AEM technology and its endorsements is continually improving and that this will benefit revenue efforts in fiscal year 2025.
• Management believes that they enter fiscal year 2025 having achieved improvements in the clinical credibility of their technology.
• Management's fiscal year 2025 operating plan is focused on growing revenue, increasing gross profits, increasing research and development costs while increasing profits and positive cash flows.

Industry Context

The report highlights the increasing adoption of minimally invasive surgery (MIS) and the associated risks of stray electrosurgical energy, which Encision's AEM technology aims to address. The company is positioning itself to capitalize on the growing demand for safer surgical instruments in the laparoscopic market, which is estimated to have $500 million in annual sales for monopolar electrosurgical instruments. The company is also seeking to expand internationally, recognizing the potential for sales outside the U.S. to be at least as large as the U.S. market.

Comparison to Industry Standards

• Encision competes with large medical device companies like Medtronic and Johnson & Johnson, which have significantly greater resources.
• Unlike competitors, Encision's AEM technology aims to completely eliminate stray electrosurgical burns, while other technologies may only reduce the risk.
• The company's focus on monopolar electrosurgery aligns with the fact that approximately 75% of surgeons use this method for laparoscopy.
• Encision's AEM technology is positioned as a standard of care, similar to previous technological advancements in electrosurgery, such as isolated electrosurgical generators and REM technology.
• The company is also aiming to follow a similar path to pulse oximetry in becoming a standard of care.

Legal Proceedings

• The company is involved in various disputes, claims, suits, investigations, and legal proceedings arising in the ordinary course of business.
• Management believes that the resolution of current pending legal matters will not have a material adverse effect on the business, financial condition, results of operations or cash flows.

Related Party Transactions

• Encision paid consulting fees of $32,032 and $55,715 to an entity owned by one of its directors in fiscal years 2024 and 2023, respectively.

Stakeholder Impact

• Shareholders may be concerned about the company's financial performance and the potential need for additional capital.
• Employees may be affected by the company's financial situation and any potential changes in operations.
• Customers (hospitals and surgeons) may benefit from the company's AEM technology, which aims to improve patient safety.
• Suppliers may be impacted by the company's financial performance and any changes in purchasing patterns.
• Creditors may be concerned about the company's ability to repay its debts.

Next Steps

• Encision plans to focus on growing its AEM franchise through a campaign focused on the clinical, economic and safety benefits of AEM technology.
• The company intends to continue developing and training its network of direct and independent sales representatives.
• Encision will continue to pursue supplier agreements with major GPOs, hospital systems, and integrated delivery networks.
• The company plans to expand its AEM product line and introduce new refinements in fiscal year 2025.
• Encision will continue to explore options to provide additional financing to fund future operations.

Key Dates

Keywords

AEM technology, electrosurgical instruments, minimally invasive surgery, laparoscopic surgery, patient safety, medical devices, surgical instruments, stray electrosurgical burns, healthcare, patents